Celebrity Inventors
Magician Harry Houdini patented a "Diver's Suit" enabling the wearer to "quickly divest himself of the suit while being submerged and to safely escape and reach the surface of the water."
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8013114 | Fusion proteins based upon somatostatin receptors The present invention is directed to fusion proteins that can be used to assay gene transfer and expression both in vitro and in vivo. The fusion proteins contain a reporter protein, e.g. a somatostatin receptor, fused to a second protein, which may be a protein fus... | 09/06/2011 |
| 7700717 | Photo-active backbone cyclized somatostatin analogs for photodynamic therapy and imaging Novel photo-active labeled diagnostic and therapeutic peptides which are conformationally constrained backbone cyclized somatostatin analogs, having improved somatostatin receptor subtype affinity and selectivity are disclosed. The backbone cyclized peptide analogs ... | 04/20/2010 |
| 7410943 | Imaging agents The invention relates to compounds of formula (I): and their use as targeting vectors that bind to receptors associated with angiogenesis. Such compounds may thus be used for diagnosis or therapy of, for example, malignant diseases, heart diseases, endometriosis, in... | 08/12/2008 |
| 7408024 | Somatostatin antagonists The present invention is directed to a somatostatin antagonist according to formula (I): A1-cyclo {D-Cys-A2-D-Trp-A3-A4-Cys}-A5Y1, wherein A1 is an optionally substituted aromatic a-amino a... | 08/05/2008 |
| 7378488 | Somatostatin antagonists The present invention is directed to a somatostatin antagonist according to formula (I), wherein A1 is an optionally substituted aromatic ∝-amino acid; A2 is an optionally substituted aromatic ∝-amino acid; A3 is Dab, Dap, Lys or... | 05/27/2008 |
| 7361642 | Canine specific growth hormone releasing hormone A composition and a method of increasing growth hormone (“GH”) values in a canine or dog, and more specifically, a canine- or dog-specific growth hormone releasing hormone (“dGHRH”), or functional biological equivalent thereof. The dGHRH is an isolated compo... | 04/22/2008 |
| 7335723 | Melanin-concentrating hormone antagonists The present invention features MCH antagonists active at the MCH-1R. The antagonists are optionally modified peptides able to inhibit the effect of MCH at MCH-1R. MCH antagonists have a variety of uses including being used as a research tool and being used to achiev... | 02/26/2008 |
| 7326685 | Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof Disclosed are peptide agents and uses thereof that are analogs of biologically active peptides such as somatostatin and bombesin. The compounds of the invention have the general formula X-Y-Z-Q, where X is a cytotoxic agent, therapeutic agent, detectable label or ch... | 02/05/2008 |
| 7321045 | Vitronectin receptor antagonist pharmaceuticals The present invention describes novel compounds of the formula: (Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. Th... | 01/22/2008 |
| 7312304 | Somatostatin agonists Claimed are a series of somatostatin agonists and uses thereof, according to formula (I), A1-cyclo[Cys-A2-D-Trp-A3-A4-Cys]-A5-Y1, (I) wherein A1, A2, A | 12/25/2007 |
| 7276251 | Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles... | 10/02/2007 |
| 7258864 | Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency The present invention provides methods and compositions for increasing the growth rates, alleviating the symptoms, or improving the metabolism of human patients having insulin-like growth factor-1 deficiency (IGFD). The invention relates to methods comprising admini... | 08/21/2007 |
| 7241737 | Urotensin-II agonists and antagonists The present invention is directed to a novel class of cyclic polypeptides of the formula: (R1)a-AA1-cyclo[AA2-AA3-AA4-AA5-AA6-Cys]-AA7-R2, pharmaceutically ... | 07/10/2007 |
| 7238775 | Receptor(SSTR4)-selective somatostatin analogs Analogs of SRIF which are selective for SSTR4 in contrast to the other cloned SRIF receptors are useful in determining tissue and cellular expression of the receptor SSTR4 and its biological role in regulating tumor growth. SRIF analog peptides, such as des-AA1... | 07/03/2007 |
| 7238339 | Bifunctional chelating compounds containing hydroxamic acid residues New types of hydroxamic acid-based bifunctional chelators are provided. These chelators are designed to chelate metal ions that can be detected either by their paramagnetic or radioactive properties. Conjugation with peptides or protein can be achieved by the presen... | 07/03/2007 |
| 7223477 | Coating powders having enhanced flexability Coating powders having a low curing temperature are comprised of an acid functional acrylic resin having an acid number between about 40 and 220, triglycidyl isocyanurate, and a curing catalyst comprising tetrabutyl ammonium bromide. Such coating powders have a stoi... | 05/29/2007 |
| 7217796 | Neutralizing human anti-IGFR antibody The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing th... | 05/15/2007 |
| 7202330 | RGD (Arg-Gly-Asp) coupled to (neuro)peptides The invention relates to compounds having a binding affinity for both the αvβ3 receptor and a (neuro)peptide receptor, in particular the somatostatin receptor, which compound comprises a first peptide part comprising at least once the amino acid sequence Arg-Gly-A... | 04/10/2007 |
| 7192570 | Compositions of somatostatin analogues In one embodiment, a composition of somatostatin analogues having the general formula: is provided wherein Z may be absent or present and when present is selected from DOTA- and DTPA-based chelators, NOTA-based c... | 03/20/2007 |
| 7176187 | Fusion proteins based upon somatostatin receptors The present invention is directed to fusion proteins that can be used to assay gene transfer and expression both in vitro and in vivo. The fusion proteins contain a reporter protein, e.g. a somatostatin receptor, fused to a second protein, which may be a protein fus... | 02/13/2007 |
| 7166697 | V-like domain binding molecules The present invention relates to binding moieties comprising at least one monomeric V-like domain (VLD) derived from a non-antibody ligand, the at least one monomeric V-like domain being characterized in that at least one CDR loop structure or part thereof is modifi... | 01/23/2007 |
| 7153933 | Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same A solid phase synthesis method for preparing peptide-spacer-lipid conjugates, the peptide-spacer-lipid conjugates synthesized by the method, and liposomes containing the peptide-spacer-lipid conjugates. The present invention provides a convenient solid phase synthes... | 12/26/2006 |
| 7148322 | Process for the preparation of echinocandin derivatives A subject of the invention is a process for the preparation of the compounds of formula (I): R being as defined in the description as well as their salts, the intermediates, the use of the dihydrochloride as a me... | 12/12/2006 |
| 7144859 | Somatostatin agonists The present invention is directed to cyclic peptides of formula (I): X-A1-cyclo(D-Cys-A3-A4-Lys-A6-A7)-A8-Y, or a pharmaceutically acceptable salt thereof. The peptides bind selectively to the somatos... | 12/05/2006 |
| 7135564 | Reusable solid support for oligonucleotide synthesis A reusable linker arm for solid support oligonucleotide synthesis, the linker arm comprising formula (a) wherein Z is a linker moiety and T is an organic radical. A method for adding one or more nucleosides on the linker arm is also described | 11/14/2006 |
| 7122622 | Peptide compounds having improved binding affinity to somatostatin receptors The invention relates to a peptide compound having an improved binding affinity to somatostatin receptors, comprising a somatostatin analogue as the peptide and a chelating group covalently linked to the N-terminal free amino group of said peptide, wherein said soma... | 10/17/2006 |
| 7091314 | Intermediates and methods for making heptapeptide oxytocin analogues More efficient and/or economical methods for synthesizing heptapeptide alcohol analogs of oxytocin are provided along with novel intermediates which are useful in synthesizing such oxytocin analogs. Efficient and economical methods for synthesizing intermediates use... | 08/15/2006 |
| 7091313 | Synthesis of template-fixed β-hairpin loop mimetics Template-fixed β-hairpin loop mimetics comprising a template corresponding to one of the structures (a), (b), (c), (d), (e), (f), (g), (h) and a template-fixed chain of 4 to 20 α-amino acid residues which, if their α-C atom is asymmetric, have L-configuration can... | 08/15/2006 |
| 7084117 | Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof The present invention relates to a method of treating vascular proliferation in a patient in need thereof. The method includes the step of administering a therapeutically effective amount of a type-1 somatostatin agonist to said patient. ... | 08/01/2006 |
| 7078413 | Compositions and methods of use for a bombesin peptide The present invention discloses a seven amino acid peptide (7AA) of bombesin. Methods for reducing the impairment respiratory tract mucosal immunity, reducing the rate of infection of the respiratory tract by pathogenic microorganisms and reducing the atrophy or dys... | 07/18/2006 |
| 7074761 | Peptides and production and use thereof The peptides and precursors thereof, inclusive salts thereof, of the present invention are useful as a pharmaceutical composition, for example as therapeutic or prophylactic agents for hormone-producing tumors, acromegaly, gigantism, dementia, gastric ulcer and the ... | 07/11/2006 |
| 7060679 | Conformationally constrained backbone cyclized somatostatin analogs Methods of use of pharmaceutical compositions and novel peptides which are conformationally constrained backbone cyclized somatostatin analogs, having somatostatin receptor subtype selectivity, are disclosed. These patterns or receptor subtype selectivity provide co... | 06/13/2006 |
| 7045503 | Radiometal-binding peptide analogues Novel metal binding ligands are disclosed that may be coupled to peptides for use in methods of diagnosis and therapy. Peptides containing the ligands are produced using a method wherein ligand introduction or cyclization can be conducted at any point during the syn... | 05/16/2006 |
| 7041642 | Fluorescent bombesin-like peptides Light emitting compounds of the formula: where R1 is a light-emitting moiety, R2 is a bombesin-like peptide and fragment, derivative or analog thereof and L is a linker moiety, which may be ... | 05/09/2006 |
| 7034003 | Somatostatin and somatostatin agonists for decreasing body weight The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. A pharmaceutical/cosmetic composition comp... | 04/25/2006 |
| 7026289 | Method and compositions for treating hyperlipidemia and other conditions The present invention relates to a method of treating hyperlipidemia and to reducing triacylglycerols, glycerol and cholesterol in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist ... | 04/11/2006 |
| 7019109 | SSTR1-selective analogs Analogs of SRIF which are selective for SSTR1 in contrast to the other cloned SRIF receptors. These analogs are useful in determining the tissue and cellular expression of the receptor SSTR1 and its biological role in the endocrine, exocrine and nervous system, as w... | 03/28/2006 |
| 6987173 | Process for the preparation of active somatotropin from inclusion bodies A process for the preparation of biologically active somatotropin from inclusion bodies of a recombinant host cell containing an inactive form of said somatotropin protein comprises the steps of: (a) contacting the inclusion bodies... | 01/17/2006 |
| 6972164 | Lithium secondary battery for use in electric vehicle A lithium secondary battery for use in electric vehicle, includes: a battery case, and an electricity-generating body including a positive electrode, a negative electrode, and a separator, the positive and the negative electrode being wound or laminated via the sepa... | 12/06/2005 |
| 6951916 | Melanocortin receptor ligands Disclosed are MC-4 and/or MC-3 receptor ligands having the formula: wherein B is a suitable linking group comprising a least one amino acid. ... | 10/04/2005 |
